MX2022003194A - Tratamiento de deterioro del comportamiento en la encefalopatia del desarrollo y epileptica. - Google Patents
Tratamiento de deterioro del comportamiento en la encefalopatia del desarrollo y epileptica.Info
- Publication number
- MX2022003194A MX2022003194A MX2022003194A MX2022003194A MX2022003194A MX 2022003194 A MX2022003194 A MX 2022003194A MX 2022003194 A MX2022003194 A MX 2022003194A MX 2022003194 A MX2022003194 A MX 2022003194A MX 2022003194 A MX2022003194 A MX 2022003194A
- Authority
- MX
- Mexico
- Prior art keywords
- developmental
- treatment
- epileptic encephalopathy
- behavioral impairment
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M21/02—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis for inducing sleep or relaxation, e.g. by direct nerve stimulation, hypnosis, analgesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
- A61M2021/0077—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus with application of chemical or pharmacological stimulus
Abstract
La presente tecnología se relaciona con los métodos para el tratamiento de problemas del comportamiento y convulsiones en un sujeto que tiene encefalopatía del desarrollo y epiléptica (DEE, por sus siglas en inglés) por medio de la administración por la vía transdérmica de una cantidad eficaz de cannabidiol (CBD) al sujeto, en donde se tratan los problemas del comportamiento en el sujeto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962901651P | 2019-09-17 | 2019-09-17 | |
PCT/US2020/051102 WO2021055499A1 (en) | 2019-09-17 | 2020-09-16 | Treatment of behavioral impairment in developmental and epileptic encephalopathy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022003194A true MX2022003194A (es) | 2022-04-11 |
Family
ID=74869217
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022003193A MX2022003193A (es) | 2019-09-17 | 2020-09-16 | Tratamiento de encefalopatia asociada al gen syngap1. |
MX2022003194A MX2022003194A (es) | 2019-09-17 | 2020-09-16 | Tratamiento de deterioro del comportamiento en la encefalopatia del desarrollo y epileptica. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022003193A MX2022003193A (es) | 2019-09-17 | 2020-09-16 | Tratamiento de encefalopatia asociada al gen syngap1. |
Country Status (12)
Country | Link |
---|---|
US (2) | US20210077421A1 (es) |
EP (2) | EP4031119A4 (es) |
JP (2) | JP2022547922A (es) |
KR (2) | KR20220063208A (es) |
CN (2) | CN114401713A (es) |
AU (2) | AU2020350605A1 (es) |
BR (2) | BR112022004175A2 (es) |
CA (2) | CA3150617A1 (es) |
IL (2) | IL291363A (es) |
JO (2) | JOP20220054A1 (es) |
MX (2) | MX2022003193A (es) |
WO (2) | WO2021055499A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2597322A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
IL303388A (en) * | 2020-12-03 | 2023-08-01 | Zynerba Pharmaceuticals Inc | Treatment of refractory convulsions |
CN116829135A (zh) * | 2021-01-28 | 2023-09-29 | Zyne制药公司 | 大麻二酚对睡眠呼吸暂停的治疗 |
CN117479930A (zh) * | 2021-04-08 | 2024-01-30 | 长矛治疗股份有限公司 | 用于治疗癫痫发作病症的药物组合物和方法 |
WO2023163801A1 (en) * | 2022-02-24 | 2023-08-31 | Q-State Biosciences, Inc. | Therapeutics for syngap haploinsufficiency |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2471523A (en) * | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
GB2487712B (en) * | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
GB2531278A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
RU2017127609A (ru) * | 2015-02-04 | 2019-03-04 | Ф. Хоффманн-Ля Рош Аг | Антисмысловые олигомеры тау-белка и их применение |
BR112017018944A2 (pt) * | 2015-03-02 | 2018-05-15 | Afgin Pharma Llc | método de tratamento de um estado ou condição de doença em humanos com um medicamento carbinóide, e, método de tratamento de um estado ou condição de doença em um mamífero diferente de um humano com medicamento(s) carbinóide(s) |
IL246790A0 (en) * | 2016-07-14 | 2016-09-29 | Friedman Doron | Self-dissolving compounds of cannabinoids |
MX2020003004A (es) * | 2017-09-19 | 2020-11-06 | Zynerba Pharmaceuticals Inc | Cannabidiol transdermico sintetico para el tratamiento de epilepsia focal en adultos. |
WO2019089583A1 (en) * | 2017-10-30 | 2019-05-09 | Endocanna Health, Inc. | Cannabinoid formulations |
GB2597322A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
-
2020
- 2020-09-16 MX MX2022003193A patent/MX2022003193A/es unknown
- 2020-09-16 MX MX2022003194A patent/MX2022003194A/es unknown
- 2020-09-16 US US17/022,494 patent/US20210077421A1/en active Pending
- 2020-09-16 BR BR112022004175A patent/BR112022004175A2/pt unknown
- 2020-09-16 WO PCT/US2020/051102 patent/WO2021055499A1/en active Application Filing
- 2020-09-16 CA CA3150617A patent/CA3150617A1/en active Pending
- 2020-09-16 WO PCT/US2020/051095 patent/WO2021055493A1/en active Application Filing
- 2020-09-16 KR KR1020227011639A patent/KR20220063208A/ko unknown
- 2020-09-16 JP JP2022515014A patent/JP2022547922A/ja active Pending
- 2020-09-16 AU AU2020350605A patent/AU2020350605A1/en active Pending
- 2020-09-16 CN CN202080065085.5A patent/CN114401713A/zh active Pending
- 2020-09-16 KR KR1020227011640A patent/KR20220066091A/ko unknown
- 2020-09-16 CA CA3151171A patent/CA3151171A1/en active Pending
- 2020-09-16 JO JOP/2022/0054A patent/JOP20220054A1/ar unknown
- 2020-09-16 CN CN202080065120.3A patent/CN114423416A/zh active Pending
- 2020-09-16 EP EP20864502.8A patent/EP4031119A4/en active Pending
- 2020-09-16 AU AU2020348310A patent/AU2020348310A1/en active Pending
- 2020-09-16 JO JOP/2022/0061A patent/JOP20220061A1/ar unknown
- 2020-09-16 BR BR112022004272A patent/BR112022004272A2/pt unknown
- 2020-09-16 EP EP20866006.8A patent/EP4031120A4/en active Pending
- 2020-09-16 JP JP2022515027A patent/JP2022547136A/ja active Pending
-
2022
- 2022-03-14 IL IL291363A patent/IL291363A/en unknown
- 2022-03-14 IL IL291362A patent/IL291362A/en unknown
- 2022-03-17 US US17/697,629 patent/US20220218625A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4031119A4 (en) | 2023-08-02 |
EP4031119A1 (en) | 2022-07-27 |
AU2020350605A1 (en) | 2022-03-31 |
IL291363A (en) | 2022-05-01 |
EP4031120A4 (en) | 2023-08-02 |
EP4031120A1 (en) | 2022-07-27 |
CN114423416A (zh) | 2022-04-29 |
CA3151171A1 (en) | 2021-03-25 |
WO2021055499A1 (en) | 2021-03-25 |
IL291362A (en) | 2022-05-01 |
US20210077421A1 (en) | 2021-03-18 |
BR112022004175A2 (pt) | 2022-05-31 |
WO2021055493A1 (en) | 2021-03-25 |
JP2022547136A (ja) | 2022-11-10 |
JOP20220054A1 (ar) | 2023-01-30 |
CA3150617A1 (en) | 2021-03-25 |
JP2022547922A (ja) | 2022-11-16 |
KR20220063208A (ko) | 2022-05-17 |
KR20220066091A (ko) | 2022-05-23 |
BR112022004272A2 (pt) | 2022-06-07 |
MX2022003193A (es) | 2022-04-11 |
CN114401713A (zh) | 2022-04-26 |
AU2020348310A1 (en) | 2022-03-31 |
US20220218625A1 (en) | 2022-07-14 |
JOP20220061A1 (ar) | 2023-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022003194A (es) | Tratamiento de deterioro del comportamiento en la encefalopatia del desarrollo y epileptica. | |
MX2023001527A (es) | Compuestos con actividad inductora de ferroptosis y metodos de uso de estos. | |
MX2022012424A (es) | Tratamiento del sindrome del cromosoma x fragil con canabidiol. | |
BR112016028964A2 (pt) | métodos de tratamento com antagonistas contra pd-1 e pd-l1 em combinação com terapia de radiação | |
MX2020005547A (es) | Moduladores de la actividad del complemento. | |
MX2021010173A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso. | |
MX2016002265A (es) | Modulacion de inmunoreceptor para tratar cancer e infecciones virales. | |
MX2023007212A (es) | Formulaciones de pulverizacion de epinefrina. | |
MX2016002263A (es) | Modulacion de inmunoreceptor para tratar cancer e infecciones virales. | |
MY194341A (en) | Method of treating a brain tumor | |
JOP20200045A1 (ar) | كانابيدْيُول تخليقي يتم تناوله عبر الأدمة لعلاج الصرع البؤري لدى البالغين | |
TN2019000019A1 (en) | Treatment and prevention of sleep disorders | |
MX2019013862A (es) | Terapia de combinacion. | |
MX2020001727A (es) | Terapia de combinacion. | |
EA202193111A1 (ru) | Композиции и способы для лечения рака | |
GB2525517A (en) | Topical preparation for pain relief | |
BR112019008241A2 (pt) | tratamento do prurigo nodular | |
MX2022014912A (es) | Tratamiento del trastorno del espectro autista con cannabidiol. | |
MX2021003006A (es) | Bacterioterapia contra proprionibacterium acnes para el tratamiento de acne. | |
BR112018073627A2 (pt) | método para tratar câncer em um paciente | |
MX2019012659A (es) | Metodos para tratar ateroesclerosis con neutralizadores gamma-cetoaldehido. | |
MX2023006551A (es) | Tratamiento de las convulsiones refractarias. | |
MX2021007076A (es) | Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol. | |
MX2021015937A (es) | Inhibicion de sirp-gamma para el tratamiento del cancer. | |
MX2021005189A (es) | Uso de tivozanib para tratar sujetos con cancer refractario. |